5/6
08:05 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
5/6
08:05 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $31.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $31.00 price target on the stock.
5/4
09:45 am
dyn
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely [Yahoo! Finance]
5/3
05:07 pm
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
5/2
04:24 pm
dyn
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Low
Report
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
5/2
04:10 pm
dyn
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Low
Report
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
4/30
07:15 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
4/22
03:33 am
dyn
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT [Yahoo! Finance]
Medium
Report
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT [Yahoo! Finance]
3/27
04:09 pm
dyn
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer [Yahoo! Finance]
Low
Report
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer [Yahoo! Finance]
3/27
04:05 pm
dyn
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
Low
Report
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
3/27
08:33 am
dyn
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium [Yahoo! Finance]
Medium
Report
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium [Yahoo! Finance]
3/27
08:30 am
dyn
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
Medium
Report
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
3/26
10:44 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
Medium
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
3/25
07:45 am
dyn
Dyne Therapeutics Announces CEO Transition [Yahoo! Finance]
Medium
Report
Dyne Therapeutics Announces CEO Transition [Yahoo! Finance]
3/25
07:30 am
dyn
Dyne Therapeutics Announces CEO Transition
Medium
Report
Dyne Therapeutics Announces CEO Transition
3/13
07:52 am
dyn
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days [Yahoo! Finance]
Low
Report
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days [Yahoo! Finance]
3/13
07:30 am
dyn
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
Low
Report
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
3/8
05:08 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Chardan Capital from $20.00 to $31.00. They now have a "buy" rating on the stock.
Medium
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Chardan Capital from $20.00 to $31.00. They now have a "buy" rating on the stock.
3/7
01:39 pm
dyn
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... [Yahoo! Finance]
Neutral
Report
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... [Yahoo! Finance]
3/6
01:35 pm
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
3/6
10:31 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $41.00. They now have a "buy" rating on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $41.00. They now have a "buy" rating on the stock.
3/6
09:36 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Piper Sandler from $27.00 to $29.00. They now have an "overweight" rating on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Piper Sandler from $27.00 to $29.00. They now have an "overweight" rating on the stock.
3/5
03:22 pm
dyn
Dyne: H2 2024 Muscle Disease Data Could Boost Value [Seeking Alpha]
Low
Report
Dyne: H2 2024 Muscle Disease Data Could Boost Value [Seeking Alpha]
3/5
08:14 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock, up previously from $44.00.
High
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock, up previously from $44.00.
3/5
07:44 am
dyn
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]